No link between the use of ranitidine and cancer risk, claims Nature

N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.

Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData

According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year

Zydus receives final approval from USFDA for Famotidine Injection

Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

USFDA approves two Opdivo-based regimens

Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers

Dr. Reddy's to commercialise Tegoprazan in India and six emerging markets

HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales

Kokilaben Dhirubhai Ambani Hospital launches third da Vinci robotic surgical system

It is the first hospital in the country to achieve the significant milestone of completing over 2600 robotic surgeries for treating patients with prostate, kidney and urinary bladder cancer